Planning

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NP47827 Multiple Sclerosis Medicines

The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)

This public procurement record has 1 release in its history.

Planning

26 Oct 2026 at 00:00

OJEU - F1 - Prior Information Notice
Summary of the contracting process

Public Services Delivery Scotland (PSD Scotland) intends to establish a framework agreement for multiple sclerosis medicines for NHS Scotland. The medicines under consideration are glatiramer acetate, interferon beta-1a, teriflunomide, dimethyl fumarate, fingolimod, natalizumab and cladribine tablets; the proposed range may change. Supply would serve NHS bodies and Integrated Joint Boards across Scotland. This is a medicines supply procurement, classified under CPV 33600000. The three product groupings are glatiramer acetate, interferon beta-1a and natalizumab; fingolimod, teriflunomide and dimethyl fumarate; and cladribine tablets.

This is at the planning stage: PSD Scotland has stated its intention to procure, but has not yet invited tenders. The buyer expects to publish a further notice on 22 January 2027. The estimated procurement value is £30,403,887, covering a maximum framework duration of 48 months, including the initial term and any extensions combined. The framework is planned in three lots. Each lot is intended to have multiple suppliers appointed by product line; the first lot is unranked, while the other two are ranked. The detailed goods and volumes are to be set out in the future tender documents. The data does not give a proposed procurement method or evaluation criteria.

The procurement is likely to suit pharmaceutical manufacturers and medicine suppliers able to supply one or more of the seven multiple sclerosis treatments under consideration to NHS Scotland. Suppliers may want to assess capability across the three product groupings, since each is planned as a multi-supplier framework by product line rather than a single-supplier award. The product range is subject to change in response to litigation, so businesses should monitor developments affecting the medicines considered for inclusion. Suppliers with established supply arrangements for NHS Scotland and the capacity to serve NHS bodies and Integrated Joint Boards across the country are well placed to prepare. The proposed framework offers a route to supply through product-specific appointments, but the buyer has not yet set out detailed volumes or tender requirements.

How relevant is this notice?

Notice Information

Notice Title

NP47827 Multiple Sclerosis Medicines

Notice Description

The Authority seeks to establish a Framework Agreement covering Multiple Sclerosis medicines. The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape): Glatiramer acetate Interferon beta-1a Teriflunomide Dimethyl fumarate Fingolimod Natalizumab Cladribine

Lot Information

Glatiramer acetate, Interferon beta-1a and Natalizumab

Supply of Glatiramer acetate, Interferon beta-1a and Natalizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Cladribine tablets

Supply of cladribine tablets to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Fingolimod, Teriflunomide and Dimethyl Fumarate

Supply of Fingolimod, Teriflunomide and Dimethyl Fumarate to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-r6ebe6-0000846657
Publication Source
Public Contracts Scotland
Latest Notice
https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=OCT567400
Current Stage
Planning
All Stages
Planning

Procurement Classification

Notice Type
OJEU - F1 - Prior Information Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Not Specified
Procurement Method Details
Not specified
Tender Suitability
Not specified
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£30,403,887 £10M-£100M
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
26 Oct 20262 days ago
Submission Deadline
Not specified
Future Notice Date
22 Jan 20273 months to go
Award Date
Not specified
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Planned
Lots Status
Planned
Awards Status
Not Specified
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
EDINBURGH
Postcode
EH12 9EB
Postcode Area
Edinburgh
Country
Scotland
Major Region (ITL 1)
TLM Scotland
Basic Region (ITL 2)
TLM1 East Central Scotland
Small Region (ITL 3)
TLM13 City of Edinburgh
Delivery Location
TLM Scotland
Local Authority
City of Edinburgh
Electoral Ward
Drum Brae/Gyle
Westminster Constituency
Edinburgh South West

Further Information

Notice Documents

  • https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=OCT567400
    NP47827 Multiple Sclerosis Medicines - The Authority seeks to establish a Framework Agreement covering Multiple Sclerosis medicines. The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape): Glatiramer acetate Interferon beta-1a Teriflunomide Dimethyl fumarate Fingolimod Natalizumab Cladribine

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...